Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Cyclerion Therapeutics

NASDAQ CYCN
$3.15 0.15 4.76%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

7.79M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
222.60K
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.86
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
2.47M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-5.97 %

Upcoming events Cyclerion Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Cyclerion Therapeutics

Stock analysis Cyclerion Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.53 27.22
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
0.69 3.54
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-0.01 9.69
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.40 -0.16
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-45.07 13.82

Price change Cyclerion Therapeutics per year

2.08$ 7.19$
Min Max

Summary analysis Cyclerion Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Cyclerion Therapeutics

Revenue and net income Cyclerion Therapeutics

All parameters

Stock news Cyclerion Therapeutics

All news
12 May 2023 в 02:20

Cyclerion Therapeutics Sell Rights of Two Neuropsychiatric Drugs for $81 Million

12 May 2023 в 02:20

Cyclerion Therapeutics Sell Rights of Two Neuropsychiatric Drugs for $81 Million

10 June 2022 в 15:06

Cyclerion Therapeutics Posts Positive Study Data for MELAS Treatment

10 June 2022 в 15:06

Cyclerion Therapeutics Posts Positive Study Data for MELAS Treatment

10 June 2022 в 15:06

Cyclerion Therapeutics Posts Positive Study Data for MELAS Treatment

10 June 2022 в 15:06

Cyclerion Therapeutics Posts Positive Study Data for MELAS Treatment

20 October 2021 в 14:50

Cyclerion Therapeutics started at buy with $14 stock price target at Truist

About company Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Address:
301 Binney Street, Cambridge, MA, United States, 02142
Company name: Cyclerion Therapeutics
Issuer ticker: CYCN
ISIN: US23255M1053
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2019-04-02
Sector: Healthcare
Industry: Biotechnology
Site: https://www.cyclerion.com

On which stock exchange are Cyclerion Therapeutics (CYCN) stocks traded?

Cyclerion Therapeutics (CYCN) stocks are traded on NASDAQ.

What is the ticker of Cyclerion Therapeutics stocks (CYCN)?

The stock ticker of Cyclerion Therapeutics’s stocks or in other words, the code is CYCN. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Cyclerion Therapeutics (CYCN) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Cyclerion Therapeutics (CYCN) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Cyclerion Therapeutics (CYCN) stocks traded?

Cyclerion Therapeutics (CYCN) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Cyclerion Therapeutics (CYCN) stocks today?

The current price of Cyclerion Therapeutics stocks on 11.05.2024 is 3.15 dollars. per share.

What is the dynamics of Cyclerion Therapeutics (CYCN) stocks from the beginning of the year?

Cyclerion Therapeutics (CYCN) quotes have increased by -10% from the beginning of the year up to 3.15 dollars. per 1 stocks.

How much did Cyclerion Therapeutics (CYCN) stocks increase in мае 2024?

This month Cyclerion Therapeutics (CYCN) quotes have increased by 3.62% to 3.15 dollars. per share.

How much are Cyclerion Therapeutics (CYCN) stocks worth?

Today, on October, 11.05.2024 Cyclerion Therapeutics’s (CYCN) stocks cost 3.15 dollars..

What is the market capitalization of Cyclerion Therapeutics (CYCN)?

Capitalization is the market value of Cyclerion Therapeutics (CYCN) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 11.05.2024, the market capitalization of Cyclerion Therapeutics (CYCN) is estimated at about 7793601 dollars.